pulmonary hypertension, primary, 2

Rare Disease

MONDO:0014134

Also known as:

SMAD9 primary pulmonary hypertensionprimary pulmonary hypertension caused by mutation in SMAD9pulmonary hypertension, primary, 2

Any primary pulmonary hypertension in which the cause of the disease is a mutation in the SMAD9 gene.

Genes

Clinical Trials

–

Newborn Screening

–

Patient Groups

–

Patient-Friendly Information

Comprehensive, easy-to-understand information about this condition

How we create this content →

Report Generation Failed

We couldn't automatically generate the report. This may be due to temporary service issues.

Companies Active in pulmonary hypertension, primary, 2

0 approved

Organizations with approved therapies for this disease

No approved therapies yet

Research is ongoing — 4 companies have orphan drug designations for this disease

Actelion Pharmaceuticals Ltd

Other

Designated

Carmel Biosciences

Other

Designated

Glaxo Wellcome Inc.

Other

Designated

Silvergate Pharmaceuticals, Inc.

Other

Designated

View all companies active in pulmonary hypertension, primary, 2

Need this data in your product?

Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.

Explore API Start Free

← Back to All Diseases